{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:21:39Z","timestamp":1788772899756,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11864-019-0638-1","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:21:00Z","timestamp":1554117660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions"],"prefix":"10.1007","volume":"20","author":[{"given":"Nicholas J.","family":"Salgia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Dara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Bergerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"issue":"8","key":"638_CR1","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530\u201340.","journal-title":"J Clin Oncol"},{"issue":"8","key":"638_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1089\/104303401750195854","volume":"12","author":"Arie Belldegrun","year":"2001","unstructured":"Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001;12(8):883\u201392.","journal-title":"Human Gene Therapy"},{"key":"638_CR3","doi-asserted-by":"crossref","unstructured":"Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004;22(7):1188\u201394.","DOI":"10.1200\/JCO.2004.06.155"},{"issue":"6","key":"638_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12032-018-1147-y","volume":"35","author":"M Alsharedi","year":"2018","unstructured":"Alsharedi M, Katz H. Check point inhibitors a new era in renal cell carcinoma treatment. Med Oncol. 2018;35(6):85.","journal-title":"Med Oncol"},{"issue":"2","key":"638_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"Bernard Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125\u201334.","journal-title":"New England Journal of Medicine"},{"issue":"9637","key":"638_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"Robert J Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"The Lancet"},{"issue":"3","key":"638_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/107327481402100308","volume":"21","author":"DE Dolan","year":"2014","unstructured":"Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21(3):231\u20137.","journal-title":"Cancer Control"},{"issue":"3","key":"638_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/1756287217748867","volume":"10","author":"S Osanto","year":"2018","unstructured":"Osanto S, van der Hulle T. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Ther Adv Urol. 2018;10(3):109\u201323.","journal-title":"Ther Adv Urol"},{"issue":"14","key":"638_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"14","key":"638_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"Robert J. Motzer","year":"2018","unstructured":"\u2022\u2022 Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390. Large scale clinical trial exploring dual checkpoint inhibition in treatment of RCC.","journal-title":"New England Journal of Medicine"},{"issue":"34","key":"638_CR11","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35(34):3851\u20138.","journal-title":"J Clin Oncol"},{"issue":"34","key":"638_CR12","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794\u20139.","journal-title":"J Clin Oncol"},{"key":"638_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"Toni K. Choueiri","year":"2018","unstructured":"\u2022 Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115\u201325. Clinical trial evaluating use of multikinase inhibitor, cabozantinib, targeting VEGF receptors, MET, and AXL.","journal-title":"European Journal of Cancer"},{"key":"638_CR14","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591\u20137.","DOI":"10.1200\/JCO.2016.70.7398"},{"issue":"6_suppl","key":"638_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/JCO.2018.36.6_suppl.578","volume":"36","author":"RJ Motzer","year":"2018","unstructured":"\u2022 Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36(6_suppl):578. Large clinical trial reporting efficacy of combined VEGF- and checkpoint inhibitor therapies.","journal-title":"J Clin Oncol"},{"key":"638_CR16","doi-asserted-by":"crossref","unstructured":"\u2022 Motzer RJ, Penkov K, Haanen JBAG, Rini BI, Albiges L, Campbell MT, et al. LBA6_PRJAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann Oncol. 2018;29(suppl_8):mdy424.036.Large clinical trial reporting efficacy of combined VEGF- and checkpoint inhibitor therapies.","DOI":"10.1093\/annonc\/mdy424.036"},{"key":"638_CR17","unstructured":"Press Release: Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in combination with Pfizer\u2019s Inlyta\u00ae (axitinib) significantly improved overall survival (OS) and progression-free survival (PFS) as first-line therapy for advanced or metastatic renal cell carcinoma (Available at: \n                      https:\/\/investors.merck.com\/news\/press-release-details\/2018\/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pfizers-Inlyta-axitinib-Significantly-Improved-Overall-Survival-OS-and-Progression-free-Survival-PFS-as-First-Line-Therapy-for-Advanced-or-Metastatic-Renal-Cell-Carcinoma\/default.aspx;\n                      \n                     last accessed 21 Dec 2018."},{"issue":"6","key":"638_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749\u201357.","journal-title":"Nat Med"},{"issue":"6","key":"638_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437\u201344.","journal-title":"Annals of Oncology"},{"issue":"6371","key":"638_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0638-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T23:20:04Z","timestamp":1585610404000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0638-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0638-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]},"assertion":[{"value":"1 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Nicholas J. Salgia declares that he has no conflict of interest. Yash Dara declares that he has no conflict of interest. Paulo Bergerot declares that he has no conflict of interest. Meghan Salgia declares that she has no conflict of interest. Sumanta K. Pal has received compensation from Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, Bristol-Myers Squibb, and Astellas for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"41"}}